W
WAVEMAN · COMPANY
EXPO · Exponent Inc
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475
← ALL COMPANIES

EXPO

EXPONENT INC
PHARMA & BIOTECH · SERVICES-MANAGEMENT CONSULTING SERVICES · CIK 0000851520
FORM 144 · 2☆ WATCH
INSIDER NET · 180D
-$1.7M
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
158
13F, latest reported quarter
REVENUE GROWTH
+4.2%
XBRL, annual
NET MARGIN
18.2%
CONVERSIONS · 180D
25
codes C/M, not in net · $1.4M priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$1.7M over 180 days
-$457.5K over 90 days
below 65% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
158 funds added or opened last quarter
more than 80% of Pharma & Biotech
REVENUE
+4.2% year over year
more than 52% of Pharma & Biotech
MARGIN
18.2% net margin
more than 88% of Pharma & Biotech
BUYBACKS
$146.1M repurchased, FY to 2026-07-03
more than 70% of Pharma & Biotech
SHORT
6.3% of shares outstanding short · 4.6 days to cover · settled 2026-07-31
more than 61% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Insiders are net sellers: -$1.7M across 5 people in 180 days.
158 funds added or opened positions in the latest 13F quarter, of 342 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -0.9%
-0.9%12M
-24%-12%-0%+12%2025-092025-102025-122026-032026-052026-072026-09 2026-02-10 · Pye John sold $278.0K2025-12-15 · Corrigan Catherine sold $228.1K2025-11-17 · Corrigan Catherine sold $226.4K2025-09-15 · Corrigan Catherine sold $225.1K2025-10-15 · Corrigan Catherine sold $215.6K2026-05-13 · Rakow Joseph sold $161.0K2026-04-15 · Corrigan Catherine sold $149.8K2026-03-16 · Corrigan Catherine sold $149.4K2026-02-17 · Corrigan Catherine sold $149.0K2026-06-15 · Corrigan Catherine sold $132.9K2026-05-15 · Corrigan Catherine sold $128.0K2026-01-15 · Corrigan Catherine sold $120.6K2025-11-17 · Corrigan Catherine sold $118.5K2025-09-15 · Corrigan Catherine sold $117.8K2026-05-13 · Sala Joseph sold $117.1K2026-05-26 · James Bradley A sold $114.9K2026-04-15 · Corrigan Catherine sold $114.9K2026-03-16 · Corrigan Catherine sold $114.6K2026-02-17 · Corrigan Catherine sold $114.3K2025-10-15 · Corrigan Catherine sold $113.8K2026-08-17 · Corrigan Catherine sold $113.1K2026-07-15 · Corrigan Catherine sold $109.0K2026-06-15 · Corrigan Catherine sold $102.4K2026-05-15 · Corrigan Catherine sold $98.8K2026-05-19 · Reiss Richard sold $98.1K2026-02-10 · Pye John sold $25.9K2026-01-02 · Pye John bought $5.9K2025-10-03 · Pye John bought $5.1K2026-08-17 · CATHERINE CORRIGAN filed to sell $114.5K2026-07-15 · CATHERINE CORRIGAN filed to sell $107.8K
INSIDER BUYINSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $1.7M sold by insiders over 180 days, 158 funds added last quarter, $222.4K in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, EXPONENT INC insiders sold a net $1.7M of stock across 149 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER
FILED
SHARES
VALUE
Corrigan Catherine
Chief Executive Officer
SELL
2026-08-17
1,707.0
$113.1K
Corrigan Catherine
Chief Executive Officer
SELL
2026-07-15
1,737.0
$109.0K
Corrigan Catherine
President & CEO
SELL
2026-06-15
1,793.0
$102.4K
Corrigan Catherine
President & CEO
SELL
2026-06-15
2,326.0
$132.9K
James Bradley A
Group Vice President
SELL
2026-05-26
2,000.0
$114.9K
149 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 144 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
BlackRock, Inc.
6,184,950.0 sh
$363.4M
KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC
3,995,684.0 sh
$234.8M
VANGUARD PORTFOLIO MANAGEMENT LLC
3,143,624.0 sh
$184.7M
VANGUARD CAPITAL MANAGEMENT LLC
2,180,212.0 sh
$128.1M
STATE STREET CORP
1,943,646.0 sh
$114.2M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
CATHERINE CORRIGAN
FILED 2026-08-17
$114.5K
CATHERINE CORRIGAN
FILED 2026-07-15
$107.8K
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
FAM SMALL CAP FUND
$12.7M POSITION · AS OF 2026-03-31
4.2%
Geneva SMID Cap Growth Fund
$1.7M POSITION · AS OF 2026-02-28
3.7%
Nationwide Geneva Small Cap Growth Fund
$30.0M POSITION · AS OF 2026-04-30
2.7%
CONESTOGA SMID CAP FUND
$13.4M POSITION · AS OF 2026-03-31
2.7%
CONESTOGA SMALL CAP FUND
$53.8M POSITION · AS OF 2026-03-31
2.4%
Royce Premier Fund
$21.1M POSITION · AS OF 2026-03-31
2.1%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Executive pay vs shareholder return
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2025
$3.7M
$2.5M
$2.0M
-18%
+57%
2024
$3.5M
$3.5M
$1.9M
+3%
+45%
2023
$3.6M
$2.8M
$1.9M
+1%
+26%
2022
$3.6M
$2.3M
$1.6M
+12%
+8%
2021
$3.0M
$5.2M
$1.5M
+31%
+25%
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2026-012025-012023-122022-12
REVENUE$582.0M$558.5M$536.8M$513.3M
OPERATING INCOME$119.8M$119.6M$111.3M$140.8M
NET INCOME$106.0M$109.0M$100.3M$102.3M
EPS (DILUTED)2.072.111.941.96
OPERATING CASH FLOW$131.7M$144.5M$127.4M$93.8M
CASH$221.9M$258.9M$187.2M$161.5M
BUYBACKS$97.1M$5.7M$24.2M$155.9M
DIVIDENDS PAID$60.4M$56.8M$54.0M$49.2M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-05 ALL SYSTEMS LIVE FOR MACHINES →